Boston – October 29, 2026 -- People with Parkinson's can now order WellPD, an FDA-cleared and CE-marked wrist-worn device from Empatica that tracks tremor, dyskinesia and bradykinesia at home, along with sleep and activity.
A companion app pulls those measurements into daily summaries. The aim is to help users see how their symptoms fluctuate, spot changes around medication doses and talk through those patterns with their care teams.
Symptoms shift by the hour, and memory is a poor logbook
Parkinson's symptoms can vary from one hour to the next, including as medication takes effect or wears off. In an appointment, recalling when changes happened, how long they lasted and how they affected daily life can be hard.
WellPD records movement and other body signals. Clinically validated algorithms translate them into measurements of motor symptoms, sleep and activity. Paired with medication logs, the data can reveal patterns such as disrupted sleep or movement changes around doses. Users can follow the daily summaries instead of relying on memory or a diary.
Family members and caregivers get another way to understand and support their loved one. Clinicians get added context about symptoms between visits.
Neurologist: objective home data complements patient feedback
Dr. Alessandro Di Rocco, system director for Parkinson's and Movement Disorders at Northwell Health, said wearables can turn a complex mix of symptoms into clear, actionable data that supports more informed care and tailored treatments.
WellPD builds on PKG Health, acquired in 2025
The device combines Empatica's medical device experience with the Parkinson's expertise of PKG Health, which Empatica acquired in 2025. The PKG algorithms are backed by more than 70 peer-reviewed publications and used in more than 150 hospitals and clinical sites worldwide. The technology also supports pharmaceutical, university and teaching-hospital research, including studies of disease progression, treatment response and digital measures in clinical trials.
WellPD ships to the US, Canada, the UK, Australia and New Zealand
WellPD is available to order in the United States, Canada, the United Kingdom, Australia and New Zealand. It is also available in these European Economic Area countries: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Spain and Sweden. The source gives no price.
The product is covered by Empatica Health Monitoring Platform for PD Monitoring, 510(k) Clearance K260374.